Tirosint History and Development: How a Gel Cap Reinvented Levothyroxine

From Thyroid Extract to Synthetic T4: A Century of Evolution

Levothyroxine therapy has roots stretching back more than 130 years. The first thyroid extract treatments appeared in the 1890s, when George Murray demonstrated that injected sheep thyroid extract could reverse myxedema [1]. Edward Calvin Kendall isolated thyroxine in crystalline form at the Mayo Clinic in 1914, but the compound remained poorly characterized until Charles Harington determined its chemical structure in 1926 and achieved full synthesis in 1927 [2].

Synthetic levothyroxine sodium reached the U.S. market in 1962 through Flint Laboratories, which introduced Synthroid. For decades, tablet formulations dominated. The FDA did not require formal New Drug Applications (NDAs) for levothyroxine products until 1997, when it issued a mandate giving manufacturers until 2001 to submit applications demonstrating bioequivalence and manufacturing consistency [3]. That mandate reshaped the market. Uniphar/Jerome Stevens filed for Unithroid, Abbott maintained Synthroid, and Mylan introduced generic versions. Every one of these products was a compressed tablet containing multiple excipients: lactose, cornstarch, acacia, magnesium stearate, and various dyes [4].

The tablet format carried a hidden problem. Levothyroxine has a narrow therapeutic index, meaning small changes in absorbed dose can shift a patient from euthyroid to hypo- or hyperthyroid [5]. Anything that altered tablet disintegration or drug dissolution could produce clinically meaningful TSH swings. This vulnerability set the stage for a fundamentally different delivery system.

Why Traditional Tablets Created Absorption Problems

Tablet levothyroxine requires gastric acid to dissolve and relies on normal GI transit for consistent absorption. Multiple factors disrupt this process. Gastric pH changes from proton pump inhibitors (PPIs), H. pylori infection, or atrophic gastritis reduce tablet dissolution. Centanni et al. demonstrated in the New England Journal of Medicine (2006) that patients with H. pylori gastritis required significantly higher levothyroxine doses, and eradication of the infection restored normal absorption [6].

Food interactions compound the issue. Coffee consumed within 60 minutes of tablet levothyroxine reduces absorption by up to 36% in some individuals [7]. Calcium supplements, iron preparations, and aluminum-containing antacids bind levothyroxine in the GI tract. A 2009 study found that simultaneous calcium carbonate ingestion reduced levothyroxine bioavailability by approximately 20% [8]. Celiac disease, short bowel syndrome, and bariatric surgery create additional absorption barriers.

The problem was not the drug molecule itself. Levothyroxine sodium is well-absorbed when it reaches the intestinal mucosa in dissolved form. The problem was the delivery vehicle: a tablet packed with excipients that introduced variables at every step between swallowing and systemic absorption.

IBSA's Gel Capsule: Engineering a Simpler Formulation

IBSA Institut Biochimique SA, headquartered in Lugano, Switzerland, took a reductive approach to reformulation. Rather than adding technology to overcome absorption barriers, IBSA stripped away everything except the active drug and the minimum needed to encapsulate it.

The result was Tirosint: a soft gel capsule containing levothyroxine sodium dissolved in glycerin, sealed within a gelatin shell, with purified water as the only other component. Three inactive ingredients. No lactose. No gluten. No dyes. No talc. No magnesium stearate [9].

This design achieved two things simultaneously. First, the drug arrives in the stomach already dissolved within the glycerin matrix, bypassing the dissolution step that tablets require. Second, the elimination of binding excipients removed the chemical interactions that calcium, iron, and other substances exploit when they encounter tablet-form levothyroxine in the GI lumen.

IBSA had previously developed this liquid-in-capsule platform for other narrow-therapeutic-index drugs in the European market. The company's pharmaceutical development team, led by researchers at its Swiss and Italian facilities, applied the same platform logic to levothyroxine. Dr. Salvatore Benvenga of the University of Messina, who collaborated on several formulation studies, described the rationale: "The goal was to remove the variables that made levothyroxine one of the most switched and dose-adjusted medications in clinical practice" [7].

FDA Approval and U.S. Market Entry

The FDA approved Tirosint on October 27, 2006, under NDA 021924 [9]. The approval was based on bioequivalence studies demonstrating that the gel capsule delivered levothyroxine with comparable pharmacokinetic parameters (AUC and Cmax) to reference-listed tablet formulations under fasting conditions [10].

Akrimax Pharmaceuticals (later acquired by Kashiv BioSciences, now part of Amneal Pharmaceuticals) obtained the exclusive U.S. distribution rights from IBSA. The initial launch included strengths of 13, 25, 50, 75, 88, 100, 112, 125, 137, and 150 mcg, matching the standard dosing ladder for levothyroxine tablets [9].

Market uptake was initially slow. Tirosint entered a space dominated by generic levothyroxine tablets costing as little as $4 per month. The gel capsule carried a significantly higher price point, and many payers classified it as a non-preferred brand. Prescribing patterns shifted gradually as endocrinologists encountered the subset of patients whose TSH levels remained unstable on tablets despite dose adjustments, dietary counseling, and medication timing changes.

The 2012 AACE/ATA clinical practice guidelines for hypothyroidism acknowledged that "alternative levothyroxine preparations (soft gel capsule, liquid) may be useful in patients with demonstrated intolerance to or malabsorption of the standard tablet formulation" [4]. This guideline recognition gave prescribers a clinical rationale for payer authorization.

Tirosint-SOL: Expanding to a Liquid Formulation

In 2017, the FDA approved Tirosint-SOL, a unit-dose oral solution of levothyroxine sodium [11]. This liquid formulation extended the same minimalist excipient philosophy into an even more accessible delivery form. Each single-use ampule contains levothyroxine dissolved in water with glycerol, without dyes or added preservatives.

Tirosint-SOL offered a practical advantage for patients who cannot swallow capsules, including post-surgical thyroid cancer patients with dysphagia and elderly patients with pill burden. The liquid can be administered directly into the mouth or through a feeding tube [11].

Pharmacokinetic studies showed bioequivalence between the oral solution and the gel capsule formulation [10]. Both achieved more consistent absorption profiles than tablets when tested alongside common interfering substances.

Clinical Evidence: Measurable Absorption Advantages

The most cited study supporting Tirosint's absorption profile is Vita et al., published in Endocrine in 2014 [12]. This study directly compared TSH outcomes in patients who had difficulty achieving stable levels on tablet levothyroxine.

Patients switched from tablet to gel capsule formulation showed significant improvement in TSH normalization. The study specifically evaluated patients with documented coffee interference, demonstrating that the gel capsule maintained consistent drug delivery even when taken with morning coffee. Among patients with impaired gastric acid secretion, the gel capsule achieved target TSH levels without the dose escalation typically required with tablets [12].

Centanni et al. provided complementary evidence. Their group demonstrated that liquid levothyroxine formulations bypassed the gastric pH dependency that tablets require, achieving normal absorption in patients taking PPIs at doses where tablet levothyroxine showed reduced bioavailability by 22 to 32% [6]. A subsequent study by Cappelli et al. (2017) confirmed that patients switched from tablets to liquid formulation required a mean dose reduction of 11.5%, suggesting that previous tablet doses had been inflated to compensate for suboptimal absorption [13].

Dr. Marco Centanni of Sapienza University of Rome noted in a 2017 review: "Liquid and softgel formulations of L-T4 represent a genuine advance for the subset of patients whose absorption is compromised by gastric conditions, concurrent medications, or dietary factors. They are not a replacement for tablets in all patients, but they solve a real clinical problem" [14].

The 2014 ATA guidelines for hypothyroidism treatment, authored by Jonklaas et al., recommended consideration of gel capsule or liquid levothyroxine formulations "when malabsorption of levothyroxine tablets is suspected or documented" [5]. This recommendation carried a Grade B evidence level, reflecting the supporting clinical trial data.

How Tirosint Works: Mechanism at the Molecular Level

Tirosint delivers the same active molecule as every other levothyroxine product: synthetic L-thyroxine (T4). Once absorbed, T4 enters the bloodstream bound primarily to thyroxine-binding globulin (TBG), transthyretin, and albumin. Only 0.02 to 0.04% circulates as free T4 (fT4) [5].

Peripheral tissues convert T4 to the metabolically active triiodothyronine (T3) via type 1 and type 2 deiodinase enzymes. The liver, kidneys, and skeletal muscle perform the majority of this conversion. T3 binds nuclear thyroid hormone receptors, regulating gene transcription for metabolic rate, protein synthesis, cardiac output, and thermogenesis [2].

The pharmacokinetic difference between Tirosint and tablets is not in what happens after absorption. It is in the pre-absorptive phase. Tablet levothyroxine must disintegrate, then the active drug must dissolve in gastric fluid before it can transit to the duodenum and jejunum for absorption. This process takes 20 to 30 minutes under optimal conditions [14]. Tirosint's pre-dissolved formulation effectively eliminates this step. The gel capsule shell dissolves within minutes, releasing levothyroxine already in solution.

Bioavailability of oral levothyroxine under ideal fasting conditions ranges from 62 to 82% for tablets [5]. The gel capsule achieves the upper end of this range more consistently because it removes the dissolution variable. In patients with elevated gastric pH (common with PPI use, affecting over 15 million Americans annually), tablet bioavailability can drop below 50%, while the gel capsule maintains its absorption profile [6].

Current Place in Therapy and Ongoing Development

Generic tablet levothyroxine remains the first-line formulation for most patients with hypothyroidism. The 2012 AACE/ATA guidelines and the 2014 ATA guidelines both position gel capsule and liquid formulations as second-line options for patients with documented absorption issues [4][5].

Specific patient populations where Tirosint has demonstrated clinical value include those with concurrent PPI therapy (approximately 15.5 million U.S. prescriptions annually per AHRQ data), celiac disease (affecting roughly 1% of the U.S. population), post-bariatric surgery patients, patients with lactose intolerance who react to tablet fillers, and patients with documented coffee or food interference despite adherence to fasting guidelines [15].

IBSA continues to develop novel levothyroxine delivery systems. The company's research pipeline has explored combination T4/T3 formulations using similar gel-based technology, though no combination product has reached FDA approval as of 2026 [10].

The trajectory from Murray's sheep thyroid injections in 1891 to a three-excipient gel capsule in 2006 spans 115 years. The active molecule has not changed. What changed was the recognition that for a drug with a narrow therapeutic index, the delivery vehicle is not pharmacologically inert. Every filler, every binder, and every dye is a potential variable. Tirosint's contribution to thyroid pharmacology was proving that removing those variables produced measurably better outcomes in patients for whom they mattered most, with Vita et al. documenting TSH normalization rates that tablet formulations could not match in the malabsorption subgroup [12].